Related Experiment Video
Updated: Nov 17, 2025
07:42
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.4K
2018-2019 Drug Updates in Solid Tumors
1Duke University Hospital, Durham, North Carolina.
Journal of the Advanced Practitioner in Oncology
|February 18, 2021
Abstract:
Sally Barbour, PharmD, BCOP, CPP, FHOPA, updated attendees on the FDA-approved therapies for initial or expanded indications for solid tumors across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and adverse event management.
Insights
This presentation reviews new FDA-approved therapies for solid tumors, including clinical trial data and best practices for safe dosing, administration, and adverse event management.
Area of Science:
- Oncology
- Pharmacology
- Clinical Therapeutics
Background:
- Solid tumors represent a significant area of unmet need in cancer treatment.
- Advances in drug development continue to offer new therapeutic options.
Purpose of the Study:
- To provide an update on recent FDA-approved therapies for solid tumors.
- To discuss supporting clinical trial data for these new treatments.
- To outline best practices for the safe and effective use of these agents.
Main Methods:
- Review of FDA-approved therapies for solid tumors within the past year.
- Analysis of supporting clinical trial data.
- Discussion of practical aspects of drug management.
Main Results:
- Several new FDA-approved therapies for initial or expanded indications in solid tumors were identified.
- Supporting clinical trial data demonstrated efficacy and safety profiles.
- Best practices for dosing, administration, monitoring, and adverse event management were detailed.
Conclusions:
- The landscape of solid tumor treatment is evolving with new FDA-approved therapies.
- Optimal patient outcomes require careful attention to dosing, administration, and toxicity management.
- Continuous education on new oncologic therapies is crucial for healthcare professionals.
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:27Tumor Immunotherapy
856
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
856
01:30Cancer Vaccines
621
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
621
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:07Tumor Progression
6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
01:26FDA Approved Drugs: Changes to Approved Drugs
78
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
78